Rankings
▼
Calendar
RCUS Q2 2021 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena
RCUS
Arcus Biosciences, Inc.
$2B
Q2 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$9M
+440.6% YoY
Gross Profit
$9M
100.0% margin
Operating Income
-$76M
-804.7% margin
Net Income
-$76M
-803.0% margin
EPS (Diluted)
$-1.09
QoQ Revenue Growth
+0.0%
Cash Flow
Operating Cash Flow
-$74M
Free Cash Flow
-$80M
Stock-Based Comp.
$13M
Balance Sheet
Total Assets
$899M
Total Liabilities
$294M
Stockholders' Equity
$605M
Cash & Equivalents
$320M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$9M
$2M
+440.6%
Gross Profit
$9M
$2M
+440.6%
Operating Income
-$76M
-$45M
-67.8%
Net Income
-$76M
-$45M
-68.5%
Revenue Segments
Gilead Access Rights
$8M
82%
Taiho Collaboration Agreement
$2M
18%
← FY 2021
All Quarters
Q3 2021 →